Reduction of Methylglyoxal-Induced Glycation by Pyridoxamine Improves Adipose Tissue Microvascular Lesions

Table 1

Body weight, glycemia, fasting and 2 hours after intraperitoneal glucose injection (1.8 g/kg), glycated hemoglobin, serum triglycerides, and total and HDL cholesterol.

Parameter	C	MG	Pyr
Body weight (g)	430 ± 17	440 ± 18	433 ± 12
Fasting glycemia (mg/dL)	63.3 ± 1	62.9 ± 1.5	64.3 ± 2
Glycemia at 2 h (mg/dL)	92.0 ± 6.1	91.3 ± 1.8	92.5 ± 3.1
HbA1c (%)	3.6 ± 0.1	3.6 ± 0.0	3.7 ± 0.1
Triglycerides (mg/dL)	95.8 ± 9.1	78.6 ± 5.6	98 ± 10.8
Total cholesterol (mg/dL)	92.5 ± 5.8	84.7 ± 4.7	91.3 ± 4.5
HDL cholesterol (mg/dL)	55.5 ± 1.2	47.3 ± 2.0*	54.8 ± 1.6^#

C: Control Wistar rats; MG: Wistar rats with methylglyoxal administration; Pyr: Wistar rats with methylglyoxal administration and pyridoxamine treatment. Data is presented as mean ± SEM, 𝑛=6 in each group. *Different from C; ^#different from MG. 1 symbol 𝑃<0.05.